Results 131 to 140 of about 8,038,703 (314)

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

open access: yesMolecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker   +16 more
wiley   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

A novel approach to analyzing the evolution of SARS-CoV-2 based on visualization and clustering of large genetic data compactly represented in operative memory

open access: yesВавиловский журнал генетики и селекции
SARS-CoV-2 is a virus for which an outstanding number of genome variants were collected, sequenced and stored from sources all around the world. Raw data in FASTA format include 16.8 million genomes, each ≈29,900 nt (nu­cleotides), with a total size of ...
A. Yu. Palyanov, N. V. Palyanova
doaj   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Investigating the Usability, Efficacy and Accuracy of a Medication Entering Software System for a Healthcare Robot. [PDF]

open access: yesFront Robot AI, 2022
Martini N   +7 more
europepmc   +1 more source

Optimizing LLM-Based Multi-Agent System with Textual Feedback: A Case Study on Software Development [PDF]

open access: green
Ming Shen   +6 more
openalex   +1 more source

Home - About - Disclaimer - Privacy